VALACICLOVIR-PHARMATHEN

UNIVADIS - VALACICLOVIR-PHARMATHEN /univadis/VALACICLOVIR-PHARMATHEN.md

ATC

Μορφές: F.C.TAB

Δραστικές

Δελτίο Τιμών 05/2018

Ημερομηνία barcode code περιεχομενο τιμή παραγωγός χονδρική λιανική
05/2018 2802921501035 292150103 VALACICLOVIR/PHARMATHEN INTERNATIONAL F.C.TAB 500MG/TAB BTx42 18.87 19.79 27.27
  • DRUGBANK - Valaciclovir
  • indication:

    For the treatment or suppression of cold sores (herpes labialis), herpes zoster (shingles), genital herpes in immunocompetent individuals, and recurrent genital herpes in HIV-infected individuals.

  • pharmacology:

  • mechanism:

    Valaciclovir is phosphorylated by viral thymidine kinase to acyclovir triphosphate (the active metabolite) which then inhibits herpes viral DNA replication by competitive inhibition of viral DNA polymerase, and by incorporation into and termination of the growing viral DNA chain. When used as a substrate for viral DNA polymerase, acyclovir triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where acyclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand.

  • toxicity:

    Adverse effects of overexposure might include headache and nausea.

  • absorprion:

    After oral administration, valaciclovir hydrochloride is rapidly absorbed from the gastrointestinal tract. The absolute bioavailability of acyclovir after administration of valaciclovir is 54.5% ± 9.1%.

  • halflife:

    2.5-3.3 hours

  • roouteelimination:

    Acyclovir accounted for 89% of the radioactivity excreted in the urine.

  • volumedistribution:

  • clearance:

    * Renal cl=255 +/- 86 mL/min [healthy] * apparent cl=86.3 +/- 21.3 mL/min/1.73 m2 [dialysis patients] * apparent cl=679.16 +/- 162.76 mL/min/1.73 m2 [healthy]